Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Madecassic acid is natural product of the triterpenoid class isolated from Centella asiatica (Umbelliferae). It exhibits anti-inflammatory activity by inhibiting iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 and downregulation of NF-κB activation in RAW 264.7 macrophage cells.
ln Vitro |
LPS-induced expression of COX-2 and iNOS is inhibited by madecassic acid (150 μM) for a 24-hour period [1].
|
---|---|
ln Vivo |
Reduce the amount of γδT17 cells and IL-17 levels in respiratory inflammatory tissues using madecassic acid (facial, 25 mg/kg, 10 days) to alleviate respiratory inflammation [2].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: RAW 264.7 mouse macrophages Tested Concentrations: 50, 100, 150 μM Incubation Duration: 24 h followed by treatment with LPS (1 µg/mL) for 4 hrs (hours) Experimental Results: Inhibition of LPS in a dose-dependent manner Induced iNOS and COX-2 protein expression. |
Animal Protocol |
Animal/Disease Models: 2.5% DSS-induced colitis in mice [2]
Doses: 25 mg/kg/day Route of Administration: po (oral gavage), 10 days Experimental Results: The number of γδT17 cells in the colon diminished. Reduce IL-17 expression in colon tissue. |
References |
[1]. Won JH, et al. Anti-inflammatory effects of madecassic acid via the suppression of NF-kappaBpathway in LPS-induced RAW 264.7 macrophage cells. Planta Med. 2010 Feb;76(3):251-7.
[2]. Xinming Yun, et al. Madecassic acid alleviates colitis-associated colorectal cancer by blocking the recruitment of myeloid-derived suppressor cells via the inhibition of IL-17 expression in γδT17 cells. Biochem Pharmacol. 2022. |
Molecular Formula |
C30H48O6
|
---|---|
Molecular Weight |
504.6985
|
Exact Mass |
504.35
|
Elemental Analysis |
C, 71.39; H, 9.59; O, 19.02
|
CAS # |
18449-41-7
|
Appearance |
Solid powder
|
SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(C[C@H]([C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)O)C)[C@@H]2[C@H]1C)C)C(=O)O
|
InChi Key |
PRAUVHZJPXOEIF-AOLYGAPISA-N
|
InChi Code |
InChI=1S/C30H48O6/c1-16-9-10-30(25(35)36)12-11-28(5)18(22(30)17(16)2)7-8-21-26(3)13-20(33)24(34)27(4,15-31)23(26)19(32)14-29(21,28)6/h7,16-17,19-24,31-34H,8-15H2,1-6H3,(H,35,36)/t16-,17+,19-,20-,21-,22+,23-,24+,26-,27+,28-,29-,30+/m1/s1
|
Chemical Name |
(1S,2R,4aS,6aR,6aS,6bR,8R,8aR,9R,10R,11R,12aR,14bS)-8,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
|
Synonyms |
Madecassic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~123.84 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9814 mL | 9.9069 mL | 19.8138 mL | |
5 mM | 0.3963 mL | 1.9814 mL | 3.9628 mL | |
10 mM | 0.1981 mL | 0.9907 mL | 1.9814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.